Lidocain Egis (Lidocaine)

Lidocaine blocks voltage‑gated sodium channels on nerve fibers, preventing the rapid influx of sodium ions that initiates an action potential. This inhibition stops nerve impulse transmission, resulting in a reversible loss of sensation in the area where the product is applied.

The appropriate dose of Lidocain Egis is determined by the prescribing healthcare professional based on the specific procedure, the size of the treatment area, and patient factors. The prescriber will provide exact instructions on the amount to apply and the frequency of use.

Safety data for topical lidocaine in pregnancy and lactation are limited. Healthcare providers generally weigh the potential benefits against any possible risks. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the use of Lidocain Egis with their physician before treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Lidocain Egis contains lidocaine, an amide‑type local anesthetic known for rapid onset and moderate duration of action. Compared with ester‑type anesthetics such as procaine, lidocaine generally offers a lower risk of allergic reactions and a more predictable pharmacokinetic profile, making it a common choice for topical skin applications.

Store Lidocain Egis at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, direct sunlight, and extreme temperatures. Ensure the container is tightly closed when not in use to maintain product stability.

Lidocain Egis is applied directly to the skin surface in a thin layer over the intended area. The recommended amount is spread evenly and allowed to absorb. It should be used on intact, non‑mucosal skin and not on large surface areas unless directed by a healthcare professional.

Serious risks include systemic toxicity, which can manifest as dizziness, seizures, or cardiac arrhythmias if excessive amounts are absorbed, and severe allergic reactions such as anaphylaxis. Rare but severe skin reactions like Stevens‑Johnson syndrome may also occur. Prompt medical attention is required if any of these symptoms develop.

Individuals with a known hypersensitivity to lidocaine or other amide‑type local anesthetics should avoid using Lidocain Egis. It is also contraindicated on broken or inflamed skin, mucous membranes, and in patients with certain cardiac conduction disorders or severe liver impairment unless specifically directed by a physician.